257 related articles for article (PubMed ID: 16796779)
21. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
[TBL] [Abstract][Full Text] [Related]
22. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
23. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
Zhu WM; Li Y; Yu C; Li N; Li JS
Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
[No Abstract] [Full Text] [Related]
24. CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients.
Oko A; Wyrwicz LS; Glyda M; Idasiak-Piechocka I; Bińczak-Kuleta A; Kaczmarczyk M; Drozd A; Ciechanowicz A; Czekalski S
Ann Acad Med Stetin; 2009; 55(2):22-6. PubMed ID: 20349607
[TBL] [Abstract][Full Text] [Related]
25. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
26. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
Mohan SR; Clemente MJ; Afable M; Cazzolli HN; Bejanyan N; Wlodarski MW; Lichtin AE; Maciejewski JP
Haematologica; 2009 Oct; 94(10):1407-14. PubMed ID: 19794084
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
Oshima K; Kanda Y; Nakahara F; Shoda E; Suzuki T; Imai Y; Watanabe T; Asai T; Izutsu K; Ogawa S; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2006 Nov; 81(11):875-9. PubMed ID: 16862551
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab.
Ravandi F; O'Brien S
Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
[TBL] [Abstract][Full Text] [Related]
30. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
32. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
33. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
34. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults.
Escribano L; Díaz Agustín Beatriz ; Bravo P; Navalón R; Almeida J; Orfao A
Leuk Lymphoma; 1999 Oct; 35(3-4):227-35. PubMed ID: 10706445
[TBL] [Abstract][Full Text] [Related]
35. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
36. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
38. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.
Ambrose LR; Morel AS; Warrens AN
Blood; 2009 Oct; 114(14):3052-5. PubMed ID: 19638623
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab in T-cell lymphoproliferative disorders.
Dearden CE; Matutes E
Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis.
Núñez-López R; Escribano L; Schernthaner GH; Prados A; Rodríguez-González R; Díaz-Agustín B; López A; Hauswirth A; Valent P; Almeida J; Bravo P; Orfao A
Br J Haematol; 2003 Jan; 120(2):257-65. PubMed ID: 12542483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
